2022 Research Funding: Phase I/II study of BET and MEK inhibition in advanced uveal melanoma
Every year, OMF donates over $150,000 to see a cure for OM. Last year's primary award, a Career Development Award for $150,000, was granted to Dr. Roger Olofsson Bagge who was conducting a Phase I clinical trial to assess the safety and efficacy of the combination of isolated hepatic perfusion (medicine directed specifically to the liver) and the checkpoint inhibitors ipilimumab and nivolumab in uveal melanoma. And this year, OMF is thrilled to be supporting another wonderful investigator with a similar $150,000 Career Development Award: Shaheer Khan, DO, Columbia University Medical Center. Read more about Dr. Khan's research >
Learn more about OMF's research funding initiatives and donate today to help fund the next breakthrough!
Learn more about OMF's research funding initiatives and donate today to help fund the next breakthrough!